In light of evidence that JAM-A may regulate expression of HER2 [4] and contribute to the development of resistance to HER2-targeted therapies in breast cancer patients [5], we sought to establish if there was a prognostic relationship between JAM-A and HER2 in GE cancers. This evidence concerns the gene F11R and breast cancer.